1-Methylpurin | 21802-40-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1-Methylpurin
• 英文别名: 1-methyl-1H-purine；1-methylpurine
• CAS: 21802-40-4
• 化学式: C₆H₆N₄
• 分子量: 134.14
• InChiKey: HOQHWHPHNGJCIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DERIVES D'ISOQUINOLINE ET METHODES D'UTILISATION
  申请人：INOTEK PHARMACEUTICALS CORP

  公开号：WO2005082368A1

  公开（公告）日：2005-09-09

  The present invention relates to Isoquinoline Derivatives, compositions comprising an effective amount of a Isoquinoline Derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease other than a cardiovascular disease, cardiovascular disease, reoxygenation injury resulting from organ transplantation, Parkinson's disease, or cancer, comprising administering to an animal in need thereof an effective amount of a Isoquinoline Derivative.

  本发明涉及异喹啉衍生物，包括含有有效量的异喹啉衍生物的组合物，以及用于治疗或预防炎症性疾病、再灌注损伤、缺血状况、肾衰竭、糖尿病、糖尿病并发症、心血管疾病以外的血管疾病、心血管疾病、器官移植导致的再氧化损伤、帕金森病或癌症的方法，包括向需要此的动物施用有效量的异喹啉衍生物。
• Isoquinoline derivatives and methods of use thereof
  申请人：Jagtap Prakash

  公开号：US20050228007A1

  公开（公告）日：2005-10-13

  The present invention relates to Isoquinoline Derivatives, compositions comprising an effective amount of a Isoquinoline Derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease other than a cardiovascular disease, cardiovascular disease, reoxygenation injury resulting from organ transplantation, Parkinson's disease, or cancer, comprising administering to an animal in need thereof an effective amount of a Isoquinoline Derivative.

  本发明涉及异喹啉衍生物、包含有效量的异喹啉衍生物的组合物以及用于治疗或预防炎症性疾病、再灌注损伤、缺血状态、肾功能衰竭、糖尿病、糖尿病并发症、心血管疾病以外的血管疾病、心血管疾病、器官移植引起的再氧化损伤、帕金森病或癌症的方法，包括向需要的动物施用有效量的异喹啉衍生物。
• [EN] TREATMENT CANCERS USING A COMBINATION COMPRISING PARP INHIBITORS, TEMOZOLOMIDE AND/OR RADIATION THERAPY<br/>[FR] TRAITEMENT DE CANCERS À L'AIDE D'UNE COMBINAISON COMPRENANT DES INHIBITEURS DE PARP, DU TÉMOZOLOMIDE ET/OU UNE RADIOTHÉRAPIE
  申请人：BEIGENE LTD

  公开号：WO2019015561A1

  公开（公告）日：2019-01-24

  Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a PARP inhibitor, particularly, (R) -2-fluoro-10a-methyl-7, 8, 9, 10, 10a, 11-hexahydro-5, 6, 7a, 11-tetraazacyclohepta [def] cyclopenta [a] fluoren-4 (5H) -one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with temozolomide and/or radiation therapy. Also, disclosed a pharmaceutical combination comprising a PARP inhibitor, particularly, (R) -2-fluoro-10a-methyl-7, 8, 9, 10, 10a, 11-hexahydro-5, 6, 7a, 11-tetraazacyclohepta [def] cyclopenta [a] fluoren-4 (5H) -one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with temozolomide and the use thereof.

  本发明涉及一种用于预防、延缓癌症进展或治疗受试者的方法，包括向需要该药物的受试者施用PARP抑制剂，特别是(R)-2-氟-10a-甲基-7、8、9、10、10a、11-六氢-5、6、7a、11-四氮杂环庚[def]环戊[a]芴-4(5H)-酮，其半水合物或其药学上可接受的盐，与替莫唑胺和/或放射治疗结合使用。此外，本发明还涉及一种药物组合物，包括PARP抑制剂，特别是(R)-2-氟-10a-甲基-7、8、9、10、10a、11-六氢-5、6、7a、11-四氮杂环庚[def]环戊[a]芴-4(5H)-酮，其半水合物或其药学上可接受的盐，与替莫唑胺的结合使用及其使用方法。
• Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
  申请人：Mitomics Inc.

  公开号：EP2339032A1

  公开（公告）日：2011-06-29

  Mitochondrial DNA (mtDNA) deletions useful for the detection of cancers and sun exposure are provided. In particular, methods and kits for detecting mitochondrial DNA deletions for the early detection, diagnosis and progression of prostate cancer, sun exposure and non-melonoma skin cancer are provided.

  提供了用于检测癌症和日晒的线粒体 DNA（mtDNA）缺失。特别是提供了检测线粒体 DNA 缺失的方法和试剂盒，用于前列腺癌、日光照射和非黑色素瘤皮肤癌的早期检测、诊断和进展。
• Nucleic acid products and methods of administration thereof
  申请人：Factor Bioscience Inc.

  公开号：US10137206B2

  公开（公告）日：2018-11-27

  The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.

  本发明部分涉及核酸，包括编码蛋白质的核酸，包含核酸的治疗剂和化妆品，向细胞、组织、器官和患者输送核酸的方法，使用核酸诱导细胞表达蛋白质的方法，用于转染、基因编辑和重编程细胞的方法、试剂盒和装置，以及使用这些方法、试剂盒和装置生产的细胞、生物体、治疗剂和化妆品。